ScreenerHero

KPRXKiora Pharmaceuticals Inc. Common Stock

NAS · US · Healthcare · Biotechnology · kiorapharma.com
2.660USD+2.31%Mkt Cap: 11.77M $P/E: —

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a poten…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap11.77M $
Enterprise Value-4.91M $
Revenue (TTM)—
Gross Profit-3.88M $
Net Income (TTM)-10.84M $
Revenue/Share—
Last Price2.660 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees13
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.17
PEG—
EV/EBITDA0.51
EV/Revenue—
P/S—
P/B0.69
EPS (TTM)-2.41
EPS (Forward)-2.23
52W Range
1.76573% of range2.990
52W High2.990 USD
52W Low1.765 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-67.19%
ROA-44.67%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-9.96M $
CapEx (TTM)110.79K $
FCF Margin—
FCF Yield-54.07%
Net Debt-16.51M $
Net Debt/EBITDA1.70
Balance Sheet
Debt/Equity0.02
Current Ratio8.97
Quick Ratio8.33
Book Value/Sh3.808 USD
Cash/Share3.806 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateAug 30, 2019
Splits
Last Split1:9
Split DateJun 11, 2024
Analyst Consensus
Rating2.0 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)12.00 USD
Upside (mean)+351.1%
Target Range12.00 USD – 12.00 USD
# Analysts1
Ownership
Shares Out.4.42M
Float3.85M
Insiders3.09%
Institutions36.26%
Short Interest
Short Ratio0.2d
Short % Float0.09%
Short % Out.0.09%
Shares Short3.86K
Short (prev mo.)7.15K
Technical
SMA 502.565 (+3.7%)
SMA 2002.311 (+15.1%)
Beta-0.34
S&P 52W Chg18.16%
Avg Vol (30d)21.11K
Avg Vol (10d)19.18K
Technical Indicators
RSI (14)57.5
MACD0.0159
MACD Signal0.0092
MACD Hist.+0.0067
BB Upper2.666 USD
BB Middle2.574 USD
BB Lower2.482 USD
BB Width7.15%
ATR (14)0.1007 USD
Vol Ratio (20d)0.77x